These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376 [TBL] [Abstract][Full Text] [Related]
3. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience. Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886 [TBL] [Abstract][Full Text] [Related]
4. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. Park JW; Jo MK; Lee HM BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371 [TBL] [Abstract][Full Text] [Related]
5. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680 [TBL] [Abstract][Full Text] [Related]
6. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135 [TBL] [Abstract][Full Text] [Related]
7. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study. Minamimoto R; Nakaigawa N; Nagashima Y; Toyohara J; Ueno D; Namura K; Nakajima K; Yao M; Kubota K Abdom Radiol (NY); 2016 Mar; 41(3):521-30. PubMed ID: 27039323 [TBL] [Abstract][Full Text] [Related]
8. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086 [TBL] [Abstract][Full Text] [Related]
9. Role of FDG PET-CT in recurrent renal cell carcinoma. Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166 [TBL] [Abstract][Full Text] [Related]
10. 18F-Fluoride PET/CT for detection of bone metastasis in patients with renal cell carcinoma: a pilot study. Sharma P; Karunanithi S; Chakraborty PS; Kumar R; Seth A; Julka PK; Bal C; Kumar R Nucl Med Commun; 2014 Dec; 35(12):1247-53. PubMed ID: 25171438 [TBL] [Abstract][Full Text] [Related]
11. [Malignant tumor with false negative 18F-FDG PET image]. Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383 [TBL] [Abstract][Full Text] [Related]
12. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma. Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314 [TBL] [Abstract][Full Text] [Related]
13. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions? Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma. Ozturk H Minerva Urol Nefrol; 2016 Jun; 68(3):263-9. PubMed ID: 25916217 [TBL] [Abstract][Full Text] [Related]
15. Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma. Bertagna F; Motta F; Bertoli M; Bosio G; Fisogni S; Tardanico R; Ferrari V; Antonelli A; Simeone C; Cosciani Cunico S; Giubbini R Nucl Med Rev Cent East Eur; 2013; 16(1):3-8. PubMed ID: 23677757 [TBL] [Abstract][Full Text] [Related]
17. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Takahashi M; Kume H; Koyama K; Nakagawa T; Fujimura T; Morikawa T; Fukayama M; Homma Y; Ohtomo K; Momose T Clin Nucl Med; 2015 Dec; 40(12):936-40. PubMed ID: 26164183 [TBL] [Abstract][Full Text] [Related]
18. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma. Ho CL; Chen S; Ho KM; Chan WK; Leung YL; Cheng KC; Wong KN; Cheung MK; Wong KK Clin Nucl Med; 2012 Nov; 37(11):1075-82. PubMed ID: 22996247 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925 [TBL] [Abstract][Full Text] [Related]
20. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma. Liu Y Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]